Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Topping this year’s survey of academic researchers is the Gladstone Institutes, a San Francisco-based nonprofit biomedical research organization with a focus on cardiovascular disease, virology and immunology, and neurodegenerative disorders that also won the top honors last year.
A couple of small West Coast research centers, the J. David Gladstone Research Institutes in San Francisco, and Sage Bionetworks in Seattle, have gotten kudos as the “Best Places to Work” in academia by The Scientist magazine.
Topping this year’s survey of academic researchers is the J. David Gladstone Institutes, a San Francisco-based nonprofit biomedical research organization with a focus on cardiovascular disease, virology and immunology, and neurodegenerative disorders that also won the top honors last year
An astonishing discovery by Deepak Srivastava and his team at the Gladstone Institutes offers hope that heart damage may one day be reversible.
The Gladstone Institutes now belong to Sandy Williams. Science, fundraising and operations are locked into Williams’ vision nearly two years after he started remaking the 33-year-old San Francisco biomedical research organization as only its second president.
Gladstone said Tuesday that it is launching a new website, tweaking its name and teaming with award-winning film maker Jesse Dylan on a series of short films about Gladstone scientists, supporters and patients who benefit from research.
Dr. Robert Grant, a researcher at the Gladstone Institutes, led one of the two studies on which Truvada's FDA approval was based—a study that showed uninfected partners taking the drug reduced their risk of acquiring HIV by 42 percent.
Cells get a makeover, cancer follows: a path to new therapies (and a warning to stem cell alchemists)
Scientists keep finding new ways to play with cells and make them alter their behavior, even their identity.
The U.S. Food and Drug Administration on Monday approved the marketing of the first drug shown to curb the transmission of the HIV virus, a development heralded by AIDS advocates and physicians as a turning point in the battle against the decades-long epidemic.
Gilead Sciences Inc.'s HIV-fighting pill Truvada was approved Monday to prevent transmission of the AIDS virus.